<DOC>
	<DOCNO>NCT00710021</DOCNO>
	<brief_summary>The purpose study explore impact vitamin D3 expression alpha interferon ( IFN alpha ) expression systemic lupus erythematosus ( SLE ) patient vitamin D deficiency .</brief_summary>
	<brief_title>Vitamin D3 Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Systemic Lupus Erythematosus ( SLE ) autoimmune disease characterized production autoantibody subsequent immune complex deposition tissue inflammation . The role interferon ( IFN ) alpha development SLE repeatedly document . Vitamin D deficiency common among lupus patient . Vitamin D recognize regulator immune response . This study explore impact vitamin D3 supplementation IFN alpha expression SLE patient . The study last approximately 12 week consist three treatment group : 1 . ) Participants receive vitamin D3 2000 IU daily 2 . ) Participants receive vitamin D3 4000 IU daily 3 . ) Participants receive vitamin D3 placebo daily . There four study visit participant . Visits occur screen , study entry , Weeks 6 12 . Physical examination , vital sign , blood urine test occur visit . For female childbearing potential , pregnancy test perform screen Week 6 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Diagnosis SLE American College Rheumatology ( ACR ) criteria Serum 25OH vitamin D level 20 ng/mL less Stable disease screening , define modify Safety Estrogens Lupus Erythematosus National Assessment SLE Disease Activity Index ( SELENASLEDAI ) 4 less Interferon ( IFN ) signature present . More information criterion find protocol Positive antidoublestranded ( antids ) DNA antibody blood test screening If corticosteroid , dose must less 20 mg per day stable 4 week prior screen study entry If immunosuppressive immunomodulatory medication azathioprine , methotrexate , leflunomide , mycophenolate , hydroxychloroquine , dose must stable 3 month prior screen study entry If receive multivitamin vitamin D supplement , dose vitamin D must 800 IU daily less stable 3 month prior screen study entry Agree use effective contraceptive method duration study Unwilling stop use drug substance may interfere fat absorption Hypercalcemia Hypercalciuria History hyperparathyroidism History kidney stone History cancer , except cervical carcinoma situ resect basal squamous cell carcinoma skin Known history chronic viral infection , include human immunodeficiency virus ( HIV ) , Hepatitis B , Hepatitis C Known active tuberculosis Any British Isles Lupus Assessment Group ( BILAG ) A B manifestation exception BILAG B mucocutaneous manifestation Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) liver function test great equal two time upper limit normal Dialysis serum creatinine great 1.5 mg/dL Expectation investigator increase corticosteroid immunosuppressive immunomodulatory medication dose screening , study entry , course study Treatment cyclophosphamide within 3 month screen Treatment rituximab within 12 month screen Other investigational drug treatment 4 week seven half live investigational drug prior study entry Drug alcohol abuse within 6 month prior study entry Treatment digoxin Treatment teriparatide Any condition , opinion investigator , would jeopardize subject 's safety follow exposure study drug Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>Vitamin D deficiency</keyword>
	<keyword>IFN alpha expression</keyword>
</DOC>